Windham Venture Partners was founded by Adam Fine, Roger Fine and Joe Proto.
Over the past decades, the team has built a reputation of trust, integrity and deep expertise in the healthcare industry. Windham Venture Partners believes the relationships with entrepreneurs and CEOs are as important as the investment itself.
Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at Coravin, GlySens, CuraSeal and HelpAround, Board Observer to SpineView, MC10, Holaira and VytronUS. Adam is a mentor in Blueprint Health, a healthcare IT accelerator in NYC. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.
Adam received his BA and graduated cum laude with distinction from Boston University and received his MBA from New York University.
Roger Fine is a co-founder and Chairman of Windham Venture Partners. Roger retired as corporate vice president and general counsel of Johnson & Johnson (J&J) after a 30-year career with the company. He served as a member of the J&J Executive Committee for 15 years. Roger is the chairman of the board of trustees of the Robert Wood Johnson Foundation, the 3rd largest foundation in the U.S. and the largest foundation in the world devoted to healthcare. He is also chairman of the board of trustees of the Child Health Institute of New Jersey. Roger currently serves on the Business Advisory Board of Healthpoint Capital, a private equity fund in New York. He is also chairman of the Foundation Venture Capital Group, an in-house VC fund focused on commercializing discoveries made by scientific faculty at the Rutgers Medical School. Roger graduated from Columbia University and earned his law degree from New York University School of Law.
Joe Proto became Chairman and Chief Executive Officer of Transactis Inc. in 2007, after nearly three decades in the billing and payments industry as a senior executive and successful entrepreneur. Prior to Transactis, he launched REMITCO, a remittance processing company, which was acquired in 2000 by First Data Corp, as well as Financial Telesis (CashFlex), which was acquired in 1992 by CoreStates, now part of Wells Fargo. Joe recently joined the Board of Directors of BillMyParents and is also an LP and Advisor in Metamorphic Ventures (focused on transactional media). Joe is a member of various financial services associations and has been a frequent speaker at conferences in the payments industry.
Lorne Taichman is Director, Science & Technology at Windham Venture Partners. Lorne has an MD degree from the University of Toronto and a PhD in Molecular Biology from the University of Wisconsin. Lorne is a professor emeritus at Stony Brook University where he directed a medical research laboratory for 30 years. His field of study was stem cells and gene and cell therapy. He has authored over 60 peer-reviewed publications and, in addition, was the recipient of an NIH MERIT award. In 2000, Lorne spent a sabbatical year at Johnson & Johnson’s Corporate Office of Science and Technology where he evaluated emerging technologies. Lorne remained as a part-time consultant to COSAT and in 2007 he left the University to join Windham. As Windham’s Director of Science & Technology, Lorne assists in locating new technologies for our review and in critically assessing the opportunity they present.
Simon Halegoua, PhD, Director, Science & Technology
Simon Halegoua is Director, Science & Technology at Windham Venture Partners. Simon has a PhD degree from Stony Brook University, post-doctoral training from the Salk Institute and has been Professor of Neuroscience at Stony Brook University for 30+ years. His laboratory has focused on issues at the crossroads of Neuroscience and Cancer, authoring both scientific publications and patents for drug targets, currently in clinical trials throughout Europe, Asia and North America. He has served as Chairman of the Dept of Neurobiology & Behavior, Principal Investigator of Individual and Program Project Grants from the NIH and is Director of the Center for Nervous System Disorders/Molecular Medicine. Simon has been consulting for the NIH, disease foundations, pharmaceutical, biotechnology and venture capital companies, and has managed a portfolio of commercial, residential and retail real estate holdings in NYC, NJ and CT. In 2012, Simon became a Windham Venture Partner and in 2014 he joined the Windham team in helping identify and critically assess investment opportunities.
Allison Russo is an Operations Associate at Windham Venture Partners. Previously, Allison worked for The Raine Group LLC, a global merchant bank focused on technology, media and telecommunications, directly supporting the financial operations team. Prior to the Raine Group, Allison held an office manager position with a healthcare-focused hedge fund.
Allison completed her undergraduate studies at State University of New York at New Paltz where she majored in Communications with a minor in Studio Art.
Windham is building an Advisory Board comprised of business leaders, scientists, clinicians, entrepreneurs and fund managers from the healthcare industry.
Riccardo Braglia is the first member of our Advisory Board. Dr. Braglia is CEO of Helsinn Holding SA, a $350mm+ Swiss specialty pharmaceutical firm focusing on supportive cancer care. Dr. Braglia comes with 27 years experience in licensing deals. In 2011 Dr. Braglia received the Ernst & Young award for the three best Swiss entrepreneurs in the High Tech/Life Sciences category. Dr. Braglia received the Award of Ernst & Young Entrepreneur of the Year 2012 in Switzerland in the category of Industry/technology/life sciences.
Brad is the CEO and Founder of Calaveras Creek Capital, collaborating with strategic partners in the formation of corporate venture funds and their management. He is a member of the board of directors at Nevro (NVRO), Cleveland Clinic Innovations, and on a corporate venture advisory board for Silicon Valley Bank, along with sitting on the boards of several private companies.
Brad recently retired from Johnson & Johnson after a 30+year career with the company. Brad was Head of Johnson & Johnson Development Corporation (JJDC) from 2012 to 2015. JJDC is J&J’s venture investing arm and has investors based in Silicon Valley, Boston, Shanghai, London and Tel Aviv. He established JJDC’s west coast office in 1997 and was an investor in medical devices, healthtech, and biotech from 1992-2012.
Dr. Vale received a PhD in Biomedical Engineering from Iowa State University and a Doctor of Veterinary Medicine from Washington State University.
Bill is a retired Managing General Partner of Healthcare Ventures, which led the strategic development and management of more than 100 companies with a combined market capitalization of more than $60 billion. Examples of HealthCare Ventures companies include Human Genome Sciences, MedImmune (acquired by Astra Zeneca), Novazyme (acquired by Genzyme), Shire, Dendreon, and FoldRx, (acquired by Pfizer). Prior to joining HealthCare Ventures, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International from 1987 to 1993. Bill currently serves on the Board of Directors for The Medicines Company, and 4 private biotech companies.
Jeffrey A. Sachs is a leading health care policy expert who has worked with federal and state governments, hospitals, health systems, health plans, behavioral health organizations, technology companies, unions and others for more than three decades.
Windham Venture Partners has partnered with Greenspring Associates to provide back office infrastructure and fund administration.
Eric Thompson, COO, GreenSpring Associates; Windham Fund Administration
Eric Thompson is the Chief Operating Officer of Greenspring Back Office Solutions (GBOS), which provides outsourced fund administration services to Windham. GBOS is a related entity of Greenspring Associates, a global venture capital fund with over $4 billion of committed capital.
Lindsay Redfield, CFO, GreenSpring Associates; Windham Fund Administration
Lindsay Redfield is the Chief Financial Officer of Greenspring Back Office Solutions (GBOS), which provides outsourced fund administration services to Windham. GBOS is a related entity of Greenspring Associates, a global venture capital fund with over $4 billion of committed capital.